Cellectis S.A.
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Cellectis S.A. sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Cellectis S.A.: 5 sponsored US clinical trials, 2 recruiting.
Cellectis S.A. sponsors 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is B-cell Non-Hodgkin Lymphoma (B-NHL), with 1 trials.
Upper-quartile sponsor footprint
Cellectis S.A. sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
5 total, page 1 of 1
Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma
NCT05607420
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
NCT04150497
Study Evaluating Safety and Efficacy of UCART123v1.2 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
NCT03190278
Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed/Refractory Multiple Myeloma (MELANI-01)
NCT04142619
Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN
NCT03203369
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 5 |
What is open in the Cellectis S.A. pipeline
2 recruiting of 5 indexed (40% open).
Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).
Top condition: B-cell Non-Hodgkin Lymphoma (B-NHL) (1 trial), 2 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Cellectis S.A.: open-pipeline peers nationwide
Peers matched on 5 registered trials and 40% open enrollment, not the therapeutic-area sidebar.
Cellectis S.A. sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 trials (± recruiting share)
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors near 40% open enrollment (± trial volume)
- Ad scientiam · 40% recruiting · 5 trials
- Alto Neuroscience · 40% recruiting · 10 trials
- Bonafide Health · 40% recruiting · 5 trials
- Brooks Rehabilitation · 40% recruiting · 5 trials
Related
What to do with this Cellectis S.A. page
5 registered trials is a research-attention snapshot, not an endorsement of Cellectis S.A. or any single study.
- 2 of Cellectis S.A.'s trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- B-cell Non-Hodgkin Lymphoma (B-NHL) is the condition Cellectis S.A. studies most, compare against other sponsors active in the same condition before evaluating a specific study. See B-cell Non-Hodgkin Lymphoma (B-NHL) trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Cellectis S.A. pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.